Arbutus Biopharma (ABUS) announced that the FDA has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABUS:
- Roivant Sciences price target raised to $34 from $30 at Jefferies
- Arbutus Biopharma price target lowered to $5.50 from $7 at Jefferies
- Arbutus Boosted by $2.25 Billion LNP Settlement and Hepatitis B Trial Progress
- Midday Fly By: Stocks climb as oil prices pull back
- Why Is Moderna (MRNA) Stock Surging Today, 3/4/26?